EP3021837A1 - Super quick disintegrating tablet formula for api miglitol - Google Patents

Super quick disintegrating tablet formula for api miglitol

Info

Publication number
EP3021837A1
EP3021837A1 EP14738534.8A EP14738534A EP3021837A1 EP 3021837 A1 EP3021837 A1 EP 3021837A1 EP 14738534 A EP14738534 A EP 14738534A EP 3021837 A1 EP3021837 A1 EP 3021837A1
Authority
EP
European Patent Office
Prior art keywords
tablets according
miglitol
particle size
tablet
tableting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14738534.8A
Other languages
German (de)
French (fr)
Inventor
Tobias Laich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of EP3021837A1 publication Critical patent/EP3021837A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • Miglitol is employed for the oral therapy of diabetes mellitus. It inhibits the rise in blood sugar level following supply of carbohydrate-containing food, by inhibiting alpha-glucosidase. For an optimum effect, the uniform distribution of the active ingredient in the food is advantageous. In order to achieve this, the possibility exists of using an orally disintegrating tablet. This then allows effective mixing in the chyme in the stomach itself.
  • the mouth feel obtained is to be pleasant especial ly for the patient, consumer, in order to increase the acceptance of the formulation and the therapeutic compliance.
  • the composition described surprisingly, achieves a tablet disintegration time in water (37°C, PhEU apparatus with disc) and in the mouth of less than 100 seconds.
  • the activ e ingredient fraction of the formulation at more than 25% (m/m), is high enough to allow production of appealingly small tablets.
  • insoluble vehicle a good 70% (m/m) overall is insoluble
  • coarse API particle size results in rapid disintegration with pleasant mouth feel and contrasts with the otherwise used technology with easily and quickly soluble vehicle/active ingredients and/or high- porosity drug forms such as freeze-dried products.
  • the tablets obtained are significantly less expensive.
  • a surprising factor is the relationship between the disintegration times measured and the particle size of the active pharmaceutical ingredient (API).
  • Favourable active ingredient agglomerates are compact (preferably crystallized) and are also achievable by customary granulation methods (preferably aqueous fluid-bed agglomeration and dry compacting) or crystallization. It is found that increasingly more compact active ingredient agglomerates with increasing average particle size lead to shorter disintegration times.
  • Figure 1 shows an example of the effect of the API particle size on the disintegration time (Ph. EU apparatus, water, 37°C).
  • the left-hand column shows the disintegration time of crystalline miglitol, the second column that of fractionated miglitol with a particle size of ⁇ 400 micrometers.
  • the third column shows the disintegration time with fractionated miglitol, with a particle size of >400 micrometes, and the right-hand column shows that of granulated miglitol. Granulation took place by fluid-bed agglomeration, and the crystalline product was fractionated by sieving.
  • a tablet of the invention contains about 20% to 30% miglitol. 25% to 28% miglitol is preferred. Moreover, the tablet of the invention contains 65% to 78%, preferably 68% to 75%, of insoluble ingredients. The difference to 100% is made up by tableting auxiliaries such as, for example, disintegration assistants, excipients, fillers, lubricants and optionally flavours.
  • the tablets can be obtained preferably by the method of direct tableting. In this method the components are merely mixed and optionally sieved, and the resulting mixture is then tableted by compression. This method is notable in particular for low production costs.
  • the active ingredient can also be processed, alone or in combination with other components of the composition described, in such a way as to form larger active ingredient agglomerates or active ingredient-containing agglomerates.
  • Suitabi lity here as well is possessed by the above-described dry compacting or other common granulation techniques, such as fluid-bed agglomeration or high-speed mixer granulat ion.
  • Granulating liquids used in such cases are preferably water or suitable organic solvents. i f, for any particular reason (e.g.
  • M iglitol drug substance of a fine part icle size grade (for example mean particle size x 50 at 3 ⁇ m-80 ⁇ m, 10 ⁇ m- 50 ⁇ m or 15 ⁇ m -30 ⁇ m ) has to be used in the described compositions, the flow properties of the resulting mixtures is markedly decreased. As a consequence the physical properties of the resulting tablets do change, but still remain within the desired range for sufficiently short disintegration time and sufficiently high mechanical resistance. The manufacturing process step of tablet compression however is negatively affected.
  • the tableting process output and robustness can be surprisingly improved with respect to the content uniformity results of the produced tablets by using a flexible foil-tubing as a connection between the container (containing the ready-to-press mixture) and the tablet press feeder.
  • the used material of this flexible foil-tubing has to be flexible enough to allow for a change in tube-diameter depending on powder flow and has to be made of suitable material for direct contact with food and pharmaceutical preparations (e.g.
  • the maximum diameter of the flexible foil-tubing is in the range of 75mm-400mm, 100mm-350mm, 150mm-300mm.
  • This described simple flexible foil-tubing is used to replace the standard metal tubing (usually stainless steel ) and all part inside the tablet press above the feeder ( forced feeder or gravity feeder).
  • This set-up ensures that powder segregat ion of the mixture is reduced to an extent, that acceptance criteria for content uniformity testing are safely met and robustness of the tableting process is greatly improved.
  • the described simple and effective modification of the process equipment helps to av oid other technical efforts that are commercially av ailable (e.g. fixed quantity supplying units, that supply small defined quantities of powder mixture to the feeder of the tablet press), allows for long v ertical transport distances for powder mixture, eliminates the need for cleaning as it can be disposed after use and needs very low investment.
  • the modified tableting process can be run with markedly improved robustness even with the fine particle size grade of Miglitol, which otherwise would not be possible.
  • M iglitol may be used alternatively as a fluid-bed granule product, in dry-compacted form (roll granules) or directly after crystallization (particularly preferred on account of no additional operating step).
  • Particularly suitable lubricants are magnesium stearate or sodium stearylfumaratc (PRUV).

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a tablet containing 20% to 30% miglitol, 65% to 78% insoluble constituents and tableting auxiliaries.

Description

Super quick disintegrating tablet formula for API miglitol. Miglitol is employed for the oral therapy of diabetes mellitus. It inhibits the rise in blood sugar level following supply of carbohydrate-containing food, by inhibiting alpha-glucosidase. For an optimum effect, the uniform distribution of the active ingredient in the food is advantageous. In order to achieve this, the possibility exists of using an orally disintegrating tablet. This then allows effective mixing in the chyme in the stomach itself.
In the field of tablets which disintegrate or dissolve rapidly in the mouth there is an extensive prior art. A noteworthy example here is a similar formulation which is described very generically and with a broad claim concerning the solubility of the active ingredient used (JP20091 14069A). Production of the new formulation ought not to necessitate any specialist technology, and the costs of the ingredients used ought to be low. The particular challenge, however, lies in the attainment of a short disintegrat ion t ime (softening time ) of the tablets in the mouth. The target figure is less than 100 seconds. This is made more difficult by the comparatively low volume of liquid in the mouth and also by the viscosity of the saliva, which is increased by comparison with that of water.
The mouth feel obtained is to be pleasant especial ly for the patient, consumer, in order to increase the acceptance of the formulation and the therapeutic compliance.
The composition described, surprisingly, achieves a tablet disintegration time in water (37°C, PhEU apparatus with disc) and in the mouth of less than 100 seconds. The activ e ingredient fraction of the formulation, at more than 25% (m/m), is high enough to allow production of appealingly small tablets. At the same time, the mechanical strength of the tablets, with a breaking load of more than 50 N and an abrasion of less than 0.5%, is sufficiently high to allow the tablets to be handled and packaged normally.
The combination of insoluble vehicle (a good 70% (m/m) overall is insoluble) combined with coarse API particle size results in rapid disintegration with pleasant mouth feel and contrasts with the otherwise used technology with easily and quickly soluble vehicle/active ingredients and/or high- porosity drug forms such as freeze-dried products. As a result of the production technology employed, moreover, the tablets obtained are significantly less expensive.
A surprising factor is the relationship between the disintegration times measured and the particle size of the active pharmaceutical ingredient (API). Favourable active ingredient agglomerates are compact (preferably crystallized) and are also achievable by customary granulation methods (preferably aqueous fluid-bed agglomeration and dry compacting) or crystallization. It is found that increasingly more compact active ingredient agglomerates with increasing average particle size lead to shorter disintegration times.
Figure 1 shows an example of the effect of the API particle size on the disintegration time (Ph. EU apparatus, water, 37°C). The left-hand column shows the disintegration time of crystalline miglitol, the second column that of fractionated miglitol with a particle size of <400 micrometers. The third column shows the disintegration time with fractionated miglitol, with a particle size of >400 micrometes, and the right-hand column shows that of granulated miglitol. Granulation took place by fluid-bed agglomeration, and the crystalline product was fractionated by sieving.
Surprisingly, in spite of the restrictive boundary conditions (methods and ingredients), success is achieved in developing a formulation which is equivalent or superior to many of the specialized technologies and/or ingredients described in the literature.
A tablet of the invention contains about 20% to 30% miglitol. 25% to 28% miglitol is preferred. Moreover, the tablet of the invention contains 65% to 78%, preferably 68% to 75%, of insoluble ingredients. The difference to 100% is made up by tableting auxiliaries such as, for example, disintegration assistants, excipients, fillers, lubricants and optionally flavours.
Production technologies employed are standard methods of the kind customary for tablet production in the pharmaceutical industry.
The tablets can be obtained preferably by the method of direct tableting. In this method the components are merely mixed and optionally sieved, and the resulting mixture is then tableted by compression. This method is notable in particular for low production costs.
It is also possible for some of the components or ail of the components to be mixed and to be compacted dry in the form of such a mixture or partial mixture. Such so-called "roll granules" are likewise inexpensive and easy to produce. Following dry compacting, the compacts are sieved and optionally mixed with the other, remaining, components, to give flowablc mixtures for tableting. This mixture is subsequently pressed into tablet form.
In order to utilize the positive effect described for the particle size of the active ingredient on the disintegration time, the active ingredient can also be processed, alone or in combination with other components of the composition described, in such a way as to form larger active ingredient agglomerates or active ingredient-containing agglomerates. Suitabi lity here as well is possessed by the above-described dry compacting or other common granulation techniques, such as fluid-bed agglomeration or high-speed mixer granulat ion. Granulating liquids used in such cases are preferably water or suitable organic solvents. i f, for any particular reason (e.g. availability of Migiitol drug substance or lack of technical equipment), M iglitol drug substance of a fine part icle size grade (for example mean particle size x50 at 3μ m-80μm, 10 μ m- 50 μ m or 15μm -30μ m ) has to be used in the described compositions, the flow properties of the resulting mixtures is markedly decreased. As a consequence the physical properties of the resulting tablets do change, but still remain within the desired range for sufficiently short disintegration time and sufficiently high mechanical resistance. The manufacturing process step of tablet compression however is negatively affected. The use of fine particle size grade of M iglitol (small crystals or milled material) results in powder segregation, which leads to inacceptabie content uni formity results for some time-points in tableting operation (content uniformity testing is a common testing approach of all major Pharmocopias like PhEU, PhJap, USP). Such a process has a high risk of producing tablets, which cannot be released/used for market supply, because of this non-compliance with the commonly employed binding regulations of content uniformity testing. Although the exact mechanism behind the observed powder segregation is not understood (e.g. difference in particle size of the mixture components, difference in density of the mixture components, irregular powder flow due to bridging etc.), the tableting process output and robustness can be surprisingly improved with respect to the content uniformity results of the produced tablets by using a flexible foil-tubing as a connection between the container (containing the ready-to-press mixture) and the tablet press feeder. The used material of this flexible foil-tubing has to be flexible enough to allow for a change in tube-diameter depending on powder flow and has to be made of suitable material for direct contact with food and pharmaceutical preparations (e.g. Polyethylene LDPE or H DPE, Polypropylene PP, Polyvinyl chlorine PVC, Polyetylenterephtalat PET, Cellulose, Si licon, Polystyrene PS, Polytetrafluoroethylene PTFE or combinations thereof). The maximum diameter of the flexible foil-tubing is in the range of 75mm-400mm, 100mm-350mm, 150mm-300mm. This described simple flexible foil-tubing is used to replace the standard metal tubing (usually stainless steel ) and all part inside the tablet press above the feeder ( forced feeder or gravity feeder). Thus a direct flexible connection with the possibility to alter its diameter between the container and the feeder of the tablet press is given. This set-up ensures that powder segregat ion of the mixture is reduced to an extent, that acceptance criteria for content uniformity testing are safely met and robustness of the tableting process is greatly improved.
The described simple and effective modification of the process equipment helps to av oid other technical efforts that are commercially av ailable (e.g. fixed quantity supplying units, that supply small defined quantities of powder mixture to the feeder of the tablet press), allows for long v ertical transport distances for powder mixture, eliminates the need for cleaning as it can be disposed after use and needs very low investment. The modified tableting process can be run with markedly improved robustness even with the fine particle size grade of Miglitol, which otherwise would not be possible.
Examples of the composition of tablets
Compacting to 8.5 mm flat tablet with facet to breaking load of 50-70 N (Schleuniger 6D)
*) M iglitol may be used alternatively as a fluid-bed granule product, in dry-compacted form (roll granules) or directly after crystallization (particularly preferred on account of no additional operating step).
**) Particularly suitable lubricants are magnesium stearate or sodium stearylfumaratc (PRUV).
The following are insoluble: maize starch, magnesium trisi licate, PVP CL.
Example of production by direct tableting
Example of agglomeration of partial mixtures by dry compacting:

Claims

Claims
1 . Tablet containing 20% to 30% miglitol, 65% to 78% insoluble constituents and tableting auxiliaries.
2. Tablet according to Claim 1 , containing 25% to 28% migl itol, 68% to 75% insoluble
constituents and tableting auxiliaries.
3. Tablet according to Claims 1 and 2, the insoluble constituents being maize starch, magnesium tr isil icate and cross-linked polyvinylpyrrolidone.
4. Tablets according to Claims 1 to 3, hav ing a disintegration time of less than 100 seconds, containing miglitol in an average particle size of 100-800 μm .
5. Tablets according to Claim 4, hav ing an average migl itol particle size of 150-600 μm .
6. Tablets according to Claim 4, hav ing an average migl itol particle size of 160-500 μm .
7. Tablets according to Claims 1 to 3, having a disintegration time of less than 100 seconds, containing miglitol in an average particle size of 3-80 μm .
8. Tablets according to Claims 1 to 3, hav ing a disintegration time of less than 100 seconds, containing miglitol in an average particle size of 10-50 um.
9. Tablets according to Claims 1 to 3, having a disintegration time of less than 100 seconds, containing miglitol in an average particle size of 15-30 μηι.
10. Tablets according to Claim 1 -9, obtainable by mixing the components and tableting the
m ixture by compression without further intermediates.
1 1. Tablets according to Claim 1 -9, obtainable by mixing the components, subjecting the mixture to initial compaction and tableting it by compression.
1 2. Tablets according to Claim 1 to 1 1 , the active ingredient migl itol being used in agglomerated form.
13. Tablets according to Claim 1 to 1 1 , the activ e ingredient being used directly after
crystallization.
14. A method of making tablets according to any of claims 1 to 13 with a tablet press wherein a flexible foi l-tubing is used as a connection between the container containing the rcady-to-press mixture and the tablet press feeder.
EP14738534.8A 2013-07-19 2014-07-14 Super quick disintegrating tablet formula for api miglitol Withdrawn EP3021837A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013150272 2013-07-19
PCT/EP2014/065016 WO2015007676A1 (en) 2013-07-19 2014-07-14 Super quick disintegrating tablet formula for api miglitol

Publications (1)

Publication Number Publication Date
EP3021837A1 true EP3021837A1 (en) 2016-05-25

Family

ID=51176393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14738534.8A Withdrawn EP3021837A1 (en) 2013-07-19 2014-07-14 Super quick disintegrating tablet formula for api miglitol

Country Status (5)

Country Link
EP (1) EP3021837A1 (en)
JP (1) JP6506752B2 (en)
CN (1) CN105377241A (en)
HK (1) HK1221915A1 (en)
WO (1) WO2015007676A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1615862A (en) * 2003-11-10 2005-05-18 浙江医药股份有限公司新昌制药厂 Miglitol oral disintegration tablet for treating diabetes II and its preparing method
JP5291324B2 (en) 2007-11-01 2013-09-18 沢井製薬株式会社 Orally disintegrating tablets
WO2009071219A2 (en) * 2007-12-08 2009-06-11 Bayer Schering Pharma Aktiengesellschaft Oral dispersable tablet
JP2009196940A (en) * 2008-02-22 2009-09-03 Takada Seiyaku Kk Tablet quickly disintegrating in oral cavity and its production method
CN102600149B (en) * 2012-02-02 2013-12-04 西藏易明西雅生物医药科技有限公司 Pharmaceutical composition for treating diabetes
WO2015008825A1 (en) * 2013-07-19 2015-01-22 株式会社三和化学研究所 Orally disintegrating tablet

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2015007676A1 *

Also Published As

Publication number Publication date
HK1221915A1 (en) 2017-06-16
JP6506752B2 (en) 2019-04-24
WO2015007676A1 (en) 2015-01-22
CN105377241A (en) 2016-03-02
JP2016533383A (en) 2016-10-27

Similar Documents

Publication Publication Date Title
RU2500388C2 (en) Orally dispersible mannitol
DE10304403A1 (en) Process for the preparation of an oral dosage form with immediate disintegration and drug release
JP7657275B2 (en) Laxative tablets
TW201124157A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
KR20080013907A (en) Stable Tablet Containing Doxydopa
JP2004315483A (en) Orally disintegrating tablet
EA028432B1 (en) New (trimethoxyphenylamino)pyrimidinyl formulations
CN118593436A (en) High performance excipients containing co-processed microcrystalline cellulose and surface-reacted calcium carbonate
TWI426913B (en) A fine grain agent having improved water-suspensibility
JP2011246428A (en) Orally disintegrating medicine and production method
US10881616B2 (en) Process of preparing active pharmaceutical ingredient salts
JP2010155865A (en) Orally disintegrable tablet
WO2015007676A1 (en) Super quick disintegrating tablet formula for api miglitol
WO2017060920A1 (en) Pharmaceutical compositions
CA2747345C (en) Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
MX2012013759A (en) Orodispersible tablets of erythritol and isomalt.
JP5680607B2 (en) Stable solid preparation and production method thereof
JP2016222696A (en) Ibuprofen sodium tablet and method for producing pharmaceutical composition containing ibuprofen sodium
TW202200207A (en) Method for the production of free-flowing granules
AU2016217658A1 (en) Method of producing a granulated composition
JP6004882B2 (en) Mannitol excipient for use in compression molding and tablets containing the same
JPWO2019131753A1 (en) Circular orally disintegrating tablet
RU2191571C1 (en) Method of chloropyramine-base tablets preparing
JP4658306B2 (en) Pharmaceutical composition for tablets
RU2203063C1 (en) Method for obtaining solid medicinal form of preparation of diuretic action

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190708

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101ALI20200225BHEP

Ipc: A61K 9/00 20060101AFI20200225BHEP

Ipc: A61K 31/445 20060101ALI20200225BHEP

INTG Intention to grant announced

Effective date: 20200312

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200723